Immunization With Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection
Maciorowski, D.; Vostal, A. C.; Bu, W.; Pytel, I. S.; Antonioli-Schmit, S.; Zhu, J.; Hoyt, F. H.; Lei, H.; Liu, G.; Kaiser, K.; Herbert, R.; Dowdell, K. C.; Schiller, J. T.; Wang, K.; Howarth, M. R.; Cohen, J. I.
Show abstract
Herpes simplex virus 2 (HSV-2) is associated with genital ulcers, neonatal encephalitis, increased risk of HIV infection, and dementia. There is no licensed HSV-2 vaccine. We developed nanoparticles displaying the HSV-2 attachment protein gD and fusion mediation protein complex gH/gL. Immunization of mice and non-human primates elicited high levels of neutralizing antibodies. Vaccination conferred robust protection in mice, preventing disease and nearly eliminating infection and shedding following HSV-2 challenge. While gD induced high neutralizing antibody titers, gH/gL contributed substantially to protection despite lower neutralization titers. Instead, gH/gL immunization generated strong fusion-blocking responses which were an important correlate of protection, showing that standard neutralization assays incompletely capture the importance of fusion-blocking activity. These findings demonstrate that targeting both HSV-2 attachment and fusion elicit complementary mechanisms for protection from infection and that neutralizing antibody alone may be insufficient for protection. Overall, these results present an innovative strategy for an HSV-2 vaccine.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.